MedPal AI (LSE:MPAL) reported its first interim results since joining AIM, marking a significant milestone as the company transitioned from a pre-revenue business to a growing healthcare platform. For the six months ended 28 February 2026, the group generated revenue of £1.6 million and gross profit of £0.37 million, while annualised revenue run rates exceeded £5 million by March.
The company recorded a post-tax loss of £3.27 million during the period, reflecting substantial investment in expanding its pharmacy operations, recruiting clinical personnel, increasing marketing activity and developing its technology platform. Despite these costs, pharmacy gross margins improved to more than 34%, highlighting the growing contribution of the group’s healthcare services.
A key focus during the period was the development of MedPal Health OS, the company’s vertically integrated healthcare platform. Progress included the acquisition of Universal Pharmacy, the launch of an NHS-contracted distance-selling pharmacy in Swaffham and the establishment of direct supply agreements with Eli Lilly and Novo Nordisk. These agreements support the company’s MedPal.clinic weight-management service, which offers GLP-1 treatments to eligible patients.
The business also expanded its presence in the care home sector through a growing business-to-business channel, with Care UK providing a significant customer relationship. Rising prescription dispensing volumes and a secondary listing in Frankfurt further increased operational scale and investor visibility.
Following the reporting period, MedPal strengthened its financial position through a £527,000 placing and a further £3.0 million fundraising. The proceeds are being used to support increasing NHS dispensing volumes and the continued expansion of MedPal.clinic. The company also completed the acquisition of the Remedi pharmacy business in Runcorn, a facility with historical annual prescription volumes approaching one million items, providing additional capacity to support future growth. Ongoing board changes are expected to further strengthen governance as the business continues to scale.
The company’s strategy remains centred on integrating digital health services, pharmacy operations and AI-enabled clinical tools into a single platform designed to improve patient engagement and healthcare delivery. Management believes recent investments and acquisitions have established a foundation for continued growth across both consumer and business markets.
More about MedPal AI Plc
MedPal AI plc is a UK-based digital healthcare company that has evolved from a health application developer into an integrated healthcare services provider. Its flagship MedPal platform aggregates data from more than 100 health applications and wearable devices, combining this information with AI-assisted clinical tools, pharmacy services and healthcare delivery solutions.
The company operates NHS-contracted and distance-selling pharmacies, robotic dispensing facilities and a private GLP-1 weight-management service. Through its growing healthcare ecosystem, MedPal serves individual consumers as well as corporate and care home customers, with recent acquisitions expanding its operational footprint and capacity across the UK.
Leave a Reply